For decades, global reproductive health advocates have pushed for expanded access to contraception, and one of the most prominent global health bodies has laid out a clear stance on the issue. Back in its 2019 Consolidated Guideline on Self-Care Interventions for Health focused on sexual and reproductive health and rights, the World Health Organization (WHO) formally issued a bold recommendation: oral contraceptive pills (OCPs) should be available directly to users without the requirement of a doctor’s prescription.
This classification marks a strong, formal recommendation from WHO, even though the organization openly acknowledges that the supporting clinical evidence carries a very low certainty rating. In justifying this unusual position, the guideline’s development group explained that after careful review, the measurable benefits of expanded access far outweigh the potential harms documented in existing research. This outcome showcases the nuanced approach WHO takes to developing public health guidance, rather than rigidly relying only on the strength of randomized clinical trial data. Experts weigh a wide range of critical factors that extend beyond lab results, including equity of access, real-world feasibility of implementation, and the stated values and preferences of people who use contraceptives regularly.
Through this framework, WHO concluded that removing the prescription barrier to OCPs delivers meaningful public health gains, especially in low-resource regions and communities where formal healthcare services are already out of reach for many. Key benefits include a projected drop in unintended pregnancies and improved long-term maternal health outcomes. The guidance does not dismiss clinical safety needs, however: it notes that medical eligibility screening remains ideal for first-time users, acknowledging that people with pre-existing underlying health conditions may require targeted clinical evaluation before starting contraception.
WHO’s position is not an isolated stance, but aligns with a growing global shift toward expanding contraceptive access. A 2022 analysis published in the WHO Bulletin examined contraceptive regulatory frameworks across 30 nations, revealing that formal, government-endorsed over-the-counter access systems remain extremely rare. The study found that only four of the 30 surveyed countries had officially added OCPs to their national over-the-counter medication lists, despite widespread informal access outside of formal regulatory rules in many more regions. The research’s authors urged nations to create clear regulatory pathways to reclassify OCPs from prescription-only to over-the-counter status, arguing that this change will drive better access and improved population health outcomes. The study also highlighted a persistent gap between written policy and on-the-ground practice: in most countries, people already access oral contraceptives without formal prescriptions on a regular basis, so aggressive enforcement of outdated prescription-only rules would only disrupt consistent access for current users.
Both the original WHO guideline and supporting research take a deliberately balanced approach to the issue, acknowledging valid concerns alongside demonstrated benefits. Beyond the well-documented gains of easier access, greater convenience, increased privacy, and enhanced reproductive autonomy, the guidance also outlines clear potential risks. These include the need for users to conduct their own medical eligibility self-assessment, the small risk of misuse without targeted clinical guidance, and the potential for increased out-of-pocket costs for users in healthcare systems where prescription medications are subsidized but over-the-counter products are not. Even with these acknowledged trade-offs, WHO’s final conclusion remains unchanged: expanding over-the-counter access delivers a net public health benefit, particularly in communities where structural barriers to routine healthcare are already severe.
Against this global consensus, one country has recently moved in the opposite direction. In an April 15, 2026 public statement, the Pharmacists Association of Belize (PAB) confirmed that it would implement new restrictive rules for OCP distribution. Under the new policy, created in close coordination with Belize’s Ministry of Health and Wellness, only current users who have previously obtained OCPs with a valid prescription will continue to be able to access them. All first-time new users are now required to get a new prescription from a licensed healthcare provider before they can obtain oral contraceptives. The policy is being rolled out through a 12-month phased enforcement of long-standing but previously under-enforced prescription requirements.
The move has already drawn sharp pushback from local advocacy and labor groups. The National Trade Union Congress of Belize (NTUCB) is among the most prominent critics, arguing that the new prescription requirement will create unnecessary access barriers for working women with limited time and resources to attend doctor’s appointments. The group also notes that the added requirement will place new, unneeded strain on Belize’s already overburdened public healthcare system, which is already struggling to meet existing patient demand.